Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment

Michèle Moreau, Lensa S. Keno, Debarghya China, Sufeng Mao, Shahinur Acter, Gnagna Sy, Hamed Hooshangnejad, Kwok Fan Chow, Erno Sajo, Jacques Walker, Philmo Oh, Eric Broyles, Kai Ding, Akila N. Viswanathan, Wilfred NgwaCancers 2024 · DOI

TL;DR

This paper introduces a novel "Liquid Immunogenic Fiducial Eluter" (LIFE) biomaterial designed to improve cervical cancer treatment. LIFE acts as both an imaging contrast agent for radiotherapy and a carrier for an immunoadjuvant, showing promise in animal models for enhancing tumor control and survival with minimal toxicity.

What Problem Does This Paper Address?

Cervical cancer, particularly in its advanced stages and in resource-poor settings, presents a significant global health challenge with limited effective treatment options and high mortality rates. Current treatments often involve lengthy regimens, side effects, and high costs, leading to disparities in care and patient outcomes. The need for innovative therapeutic approaches that can improve survival, reduce treatment burden, and increase accessibility is critical. Specifically, image-guided radiotherapy requires precise targeting, and while fiducial markers are used, there's a desire for more advanced solutions that can also contribute to therapeutic efficacy.

Methods

The core innovation is the Liquid Immunogenic Fiducial Eluter (LIFE) Biomaterial. This material is a hydrogel composed of natural biodegradable polymers (chitosan and sodium alginate) mixed with nanoparticles (titanium dioxide for CT contrast and gadolinium-based nanoparticles for MRI contrast). Crucially, it's designed to elute an immunoadjuvant, specifically anti-CD40 monoclonal antibody, directly at the tumor site.

The study employed several key methods:

  • Biomaterial Preparation: Chitosan and sodium alginate hydrogels were combined with TiO2 and gadolinium nanoparticles. The anti-CD40 antibody was then loaded into this mixture.
  • Imaging Studies:
    • In vivo: LIFE Biomaterial was injected into subcutaneous cervical tumors in C57BL6 mice, and CT and MRI scans were performed over several weeks to assess its contrast-providing capabilities.
  • Ex vivo: The biomaterial was injected into human cadavers, and CT and MRI imaging were conducted to evaluate its performance in a human anatomical context.
  • Therapeutic Efficacy Study: C57BL6 mice with bilateral subcutaneous cervical tumors were used. One tumor was treated with LIFE Biomaterial (loaded with anti-CD40), with or without a single fraction of 6 Gy radiotherapy. Tumor growth and survival were monitored.
  • Pharmacodynamics/Toxicity Study: Healthy C57BL6 mice were treated with LIFE Biomaterial (with or without anti-CD40) to assess its safety. This involved comprehensive biochemical analysis (hepatic and renal function), complete blood count, and histopathological examination of various organs over time.

Datasets

Not discussed in the paper. The study primarily used in vivo animal models (C57BL6 mice) and ex vivo human cadavers.

Key Insights and Ideas

  • Multifunctionality is Key: The LIFE Biomaterial isn't just a passive contrast agent; it's designed to be a "smart" material that actively contributes to treatment by delivering an immunoadjuvant. This dual functionality is a significant advancement over traditional fiducials.
  • Image Guidance Synergy: The biomaterial provides clear CT and MRI contrast, which is essential for precise radiotherapy targeting, especially in hypo-fractionated regimens. This addresses a critical need in image-guided cancer therapy.
  • Immunoadjuvant Delivery: Local delivery of anti-CD40 via the LIFE Biomaterial appears to prime an anti-tumor immune response, leading to not only local tumor control but also control of distant (untreated) tumors. This suggests an "abscopal effect" or systemic immune activation.
  • Potential for Reduced Treatment Burden: The combination of improved imaging and enhanced therapeutic efficacy could potentially lead to shorter treatment durations and reduced overall treatment costs, which is particularly impactful for resource-limited settings.
  • Favorable Safety Profile: The toxicity studies in healthy mice showed minimal adverse effects, suggesting that LIFE Biomaterial is well-tolerated and safe for in vivo use.

Key Results

  • Imaging Contrast: LIFE Biomaterial provided sustained CT and MR imaging contrast over several weeks in mice and was visualized in human cadavers.
  • Tumor Growth Inhibition: The combination of LIFE Biomaterial (loaded with anti-CD40) and radiotherapy significantly inhibited tumor growth in both treated and untreated tumors in mice.
  • Prolonged Survival: Mice treated with the combination therapy showed significantly prolonged survival compared to control groups.
  • Minimal Toxicity: Biochemical and histopathological analyses in healthy mice indicated minimal to no significant toxicity from LIFE Biomaterial, with or without anti-CD40.

Limitations and Future Work

  • Biodegradation Timeline: The paper acknowledges that the exact timeframe for LIFE Biomaterial biodegradation and cessation of imaging contrast provision has not yet been established. Ongoing studies aim to characterize this.
  • Dose Optimization: While promising, the study suggests that further optimization of anti-CD40 dosage, radiotherapy fractionation schedules, and other parameters is needed to fully explore the potential of this approach.
  • Animal Model Limitations: The use of a subcutaneous cervical cancer model is noted as a simplification. Future studies could benefit from orthotopic or genetic models for greater biological relevance.
  • Immune Response Characterization: While the immunoadjuvant effect is evident, further investigation into the specific cytokine release, immune cell populations, and surface molecule expression would provide deeper insights into the mechanism of action.
  • Clinical Translation: The study is pre-clinical. The next steps would involve further refinement and eventual clinical trials to translate these promising findings to human patients.

Summary updated

Abstract

Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (* <i>p</i> < 0.05) were consistently observed for groups treated with the combination of radiotherapy and LIFE Biomaterial, highlighting the potential for this strategy. Minimal toxicity was observed for healthy mice treated with LIFE Biomaterial with/without anti-CD40 in comparison to non-treated cohorts. The results demonstrate promise for the further development and clinical translation of this approach to enhance the survival and quality of life of patients with advanced cervical cancer.
BibTeX
@inproceedings{moreau2024investigating,
  author = {Michèle Moreau and Lensa S. Keno and Debarghya China and Sufeng Mao and Shahinur Acter and Gnagna Sy and Hamed Hooshangnejad and Kwok Fan Chow and Erno Sajo and Jacques Walker and Philmo Oh and Eric Broyles and Kai Ding and Akila N. Viswanathan and Wilfred Ngwa},
  title = {{Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment}},
  booktitle = {Cancers},
  year = {2024},
  doi = {10.3390/cancers16061212},
}
Figure